Tetrandrine inhibits activation of rat hepatic stellate cells in vitro via transforming growth factor-β signaling

Figure 1 Immunocytochemistry analysis of α-SMA of HSCs subjected to different treatment of tetrandrine (magnification ×200). A: control; B: tetrandrine 0.25 mg/L; C: tetrandrine 0.5 mg/L; D: tetrandrine 1 mg/L; E: tetrandrine 2 mg/L.

Figure 2 Expression of α-SMA in culture-activated HSCs. ^bP<0.01 vs control group. ^dP<0.01 vs tetrandrine 0.25 mg/L group. ^fP<0.01 vs tetrandrine 0.25, 0.5 mg/L groups.

Figure 3 RT-PCR determination of Smad 7 and TGF-β₁ mRNA expressions. Lane 1: 100-bp marker, lane 2: control group, lanes 3-6: treatment with tetrandrine at 0.25, 0.5, 1.0, 2.0 mg/L, respectively.

Figure 4 Radioimmunoassay of LN and PCIII. ^aP<0.05 vs control group.

Figure 5 Immunoblot analysis for Smad 7. C: control group, Tet-1: treatment with tetrandrine at 1 mg/L, M: protein marker.